PBMs Under Pressure

  • headshot
    Jasmine Johnson, PharmD Senior Consultant

Pharmacy benefit managers have come under intense scrutiny in recent months from the Federal Trade Commission (FTC), which has accused PBMs of driving up the prices of specialty drugs and monopolizing the distribution of those products. While the full fallout of the FTC’s actions is yet to be seen, this article outlines the potential implications for manufacturers of specialty products.

Download the White Paper

"*" indicates required fields

*Required field
This field is for validation purposes and should be left unchanged.